OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of “Hold” by Brokerages

OPKO Health, Inc. (NASDAQ:OPK) has been given an average recommendation of “Hold” by the five analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $1.55.

Several equities research analysts have recently issued reports on OPK shares. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. Finally, HC Wainwright restated a “buy” rating on shares of OPKO Health in a research report on Wednesday, July 29th.

OPKO Health Price Performance

NASDAQ OPK opened at $1.57 on Tuesday. The company has a 50-day moving average price of $1.40 and a 200-day moving average price of $1.31. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.73. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.17 billion, a P/E ratio of -17.44 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.07. The company had revenue of $163.58 million during the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.19) earnings per share. Equities research analysts anticipate that OPKO Health will post -0.23 earnings per share for the current year.

Hedge Funds Weigh In On OPKO Health

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of OPKO Health in the second quarter worth about $55,468,000. Geode Capital Management LLC grew its stake in OPKO Health by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after acquiring an additional 67,973 shares in the last quarter. Millennium Management LLC increased its position in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. increased its position in shares of OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after acquiring an additional 3,600,378 shares during the period. Finally, UBS Group AG raised its stake in shares of OPKO Health by 12.1% during the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock valued at $6,745,000 after acquiring an additional 577,248 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Its diagnostics business includes BioReference Laboratories, which provides clinical laboratory testing and specialty diagnostic services in the United States, and the 4Kscore test, a blood-based test designed to help assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical activities include products and development programs in areas such as endocrinology, nephrology, and other specialty-care markets.